Case Report: Reversal of Integrase Inhibitor– and Tenofovir Alafenamide–Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF

We report a case of substantial weight gain in a virologically suppressed patient with HIV after changing his antiretroviral therapy from efavirenz/emtricitabine/tenofovir DF to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide with subsequent rapid weight loss upon switching back. The rol...

Descripción completa

Detalles Bibliográficos
Autores principales: Pohlman, F Will, McGee, Kara S, McKellar, Mehri S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Novel ID Cases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379714/
https://www.ncbi.nlm.nih.gov/pubmed/34430674
http://dx.doi.org/10.1093/ofid/ofab403
_version_ 1783741064777039872
author Pohlman, F Will
McGee, Kara S
McKellar, Mehri S
author_facet Pohlman, F Will
McGee, Kara S
McKellar, Mehri S
author_sort Pohlman, F Will
collection PubMed
description We report a case of substantial weight gain in a virologically suppressed patient with HIV after changing his antiretroviral therapy from efavirenz/emtricitabine/tenofovir DF to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide with subsequent rapid weight loss upon switching back. The role of antiretrovirals in weight gain and loss and patient- and HIV-specific factors are discussed.
format Online
Article
Text
id pubmed-8379714
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-83797142021-08-23 Case Report: Reversal of Integrase Inhibitor– and Tenofovir Alafenamide–Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF Pohlman, F Will McGee, Kara S McKellar, Mehri S Open Forum Infect Dis Novel ID Cases We report a case of substantial weight gain in a virologically suppressed patient with HIV after changing his antiretroviral therapy from efavirenz/emtricitabine/tenofovir DF to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide with subsequent rapid weight loss upon switching back. The role of antiretrovirals in weight gain and loss and patient- and HIV-specific factors are discussed. Oxford University Press 2021-08-02 /pmc/articles/PMC8379714/ /pubmed/34430674 http://dx.doi.org/10.1093/ofid/ofab403 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Novel ID Cases
Pohlman, F Will
McGee, Kara S
McKellar, Mehri S
Case Report: Reversal of Integrase Inhibitor– and Tenofovir Alafenamide–Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF
title Case Report: Reversal of Integrase Inhibitor– and Tenofovir Alafenamide–Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF
title_full Case Report: Reversal of Integrase Inhibitor– and Tenofovir Alafenamide–Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF
title_fullStr Case Report: Reversal of Integrase Inhibitor– and Tenofovir Alafenamide–Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF
title_full_unstemmed Case Report: Reversal of Integrase Inhibitor– and Tenofovir Alafenamide–Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF
title_short Case Report: Reversal of Integrase Inhibitor– and Tenofovir Alafenamide–Related Weight Gain After Switching Back to Efavirenz/Emtricitabine/Tenofovir DF
title_sort case report: reversal of integrase inhibitor– and tenofovir alafenamide–related weight gain after switching back to efavirenz/emtricitabine/tenofovir df
topic Novel ID Cases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8379714/
https://www.ncbi.nlm.nih.gov/pubmed/34430674
http://dx.doi.org/10.1093/ofid/ofab403
work_keys_str_mv AT pohlmanfwill casereportreversalofintegraseinhibitorandtenofoviralafenamiderelatedweightgainafterswitchingbacktoefavirenzemtricitabinetenofovirdf
AT mcgeekaras casereportreversalofintegraseinhibitorandtenofoviralafenamiderelatedweightgainafterswitchingbacktoefavirenzemtricitabinetenofovirdf
AT mckellarmehris casereportreversalofintegraseinhibitorandtenofoviralafenamiderelatedweightgainafterswitchingbacktoefavirenzemtricitabinetenofovirdf

Ejemplares similares